Azmi Nabulsi Sells 7,886 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Azmi Nabulsi sold 7,886 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total value of $51,968.74. Following the completion of the transaction, the chief operating officer now directly owns 233,390 shares in the company, valued at approximately $1,538,040.10. This represents a 3.27 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Azmi Nabulsi also recently made the following trade(s):

• On Thursday, December 19th, Azmi Nabulsi sold 1,118 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $8.00, for a total transaction of $8,944.00.

Phathom Pharmaceuticals Stock Up 2.6 %

Phathom Pharmaceuticals stock traded up $0.18 during mid-day trading on Thursday, reaching $7.17. 649,136 shares of the company’s stock traded hands, compared to its average volume of 943,045. Phathom Pharmaceuticals, Inc. has a 12-month low of $6.07 and a 12-month high of $19.71. The company has a market cap of $490.28 million, a price-to-earnings ratio of -1.26 and a beta of 0.56. The stock has a 50 day moving average of $8.08 and a two-hundred day moving average of $12.53.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its earnings results on Thursday, November 7th. The company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.57) by $0.25. The business had revenue of $16.35 million for the quarter, compared to analysts’ expectations of $12.54 million. During the same quarter in the prior year, the company posted ($0.76) earnings per share. As a group, sell-side analysts forecast that Phathom Pharmaceuticals, Inc. will post -4.74 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Thursday, December 12th.

Hedge Funds Weigh In On Phathom Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Jennison Associates LLC raised its holdings in Phathom Pharmaceuticals by 112.7% during the 3rd quarter. Jennison Associates LLC now owns 5,866,389 shares of the company’s stock valued at $106,064,000 after buying an additional 3,108,810 shares during the period. Portolan Capital Management LLC raised its stake in shares of Phathom Pharmaceuticals by 50.4% in the third quarter. Portolan Capital Management LLC now owns 1,699,918 shares of the company’s stock valued at $30,735,000 after acquiring an additional 569,829 shares during the period. Checkpoint Capital L.P. lifted its holdings in shares of Phathom Pharmaceuticals by 71.9% in the 3rd quarter. Checkpoint Capital L.P. now owns 1,504,307 shares of the company’s stock worth $27,198,000 after acquiring an additional 629,307 shares during the last quarter. FMR LLC lifted its holdings in shares of Phathom Pharmaceuticals by 49,000.7% in the 3rd quarter. FMR LLC now owns 1,304,114 shares of the company’s stock worth $23,578,000 after acquiring an additional 1,301,458 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Phathom Pharmaceuticals by 17.5% during the 3rd quarter. State Street Corp now owns 922,788 shares of the company’s stock worth $16,684,000 after purchasing an additional 137,539 shares during the period. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.